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Abstract
Background: Statins have anti-inflammatory and immunomodulatory properties in addition to
their lipid-lowering effects. Currently, the effects of statins on multiple sclerosis are still
controversial. Therefore, randomized clinical trials are needed to provide better evidence on the
therapeutic potential of statins in multiple sclerosis. The SWiss Atorvastatin and Interferon Beta-
1b trial in Multiple Sclerosis (SWABIMS) evaluates the efficacy, safety and tolerability of atorvastatin
40 mg per os daily and subcutaneous interferon beta-1b every other day compared to
monotherapy with subcutaneous interferon beta-1b every other day in patients with relapsing-
remitting multiple sclerosis.
Methods/Design: SWABIMS is a multi-centre, randomized, parallel-group, rater-blinded, Phase
IIb-study conducted in eight hospitals in Switzerland. 80 treatment naïve patients with relapsing-
remitting forms of multiple sclerosis will receive subcutaneous interferon beta-1b for three
months. Afterwards, they are randomized into two equal-sized parallel arms, receiving atorvastatin
40 mg/d or not in addition to interferon beta-1b for another 12 months. Disease activity measured
by the proportion of patients with new T2 lesions is the primary endpoint.
Discussion: SWABIMS is designed to give further information about the therapeutic effect of
atorvastatin 40 mg per os daily as add-on therapy to interferon beta-1b in patients with relapsing-
remitting multiple sclerosis. Furthermore important safety and tolerability data will be generated.
Trial Registration: http://www.clinicaltrials.gov. Identifier: NCT00942591; Swissmedic reference
number: 2005DR2119
Background
Multiple Sclerosis (MS) is a chronic inflammatory disor-
der of the central nervous system involving autoimmune
mechanisms [1]. At present, there is no cure for multiple
sclerosis and the management of MS patients requires
treatment with disease-modifying agents such as inter-
feron beta (IFNB), glatiramer acetate, natalizumab or
immunsuppressants such as mitoxantrone, azathioprine
or methotrexate.
Interferon beta-1b (Betaseron®, Betaferon®) is a non-glyc-
osylated recombinant human IFNB approved for high-fre-
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micro g, 8 million International Units [MIU] every other
day [e.o.d]). It reduces the relapse rate and increases the
proportion of relapse-free patients with relapsing-remit-
ting MS (RRMS) compared to placebo. It also reduces
relapse severity, hospitalisations, and disease activity
assessed by magnetic resonance imaging (MRI), and
lengthens the time to a next relapse [2].
Statins are lipid-lowering oral drugs which inhibit the 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA-)
reductase, the main regulatory enzyme of cholesterol bio-
synthesis. In addition to their lipid-lowering effects, stat-
ins have anti-inflammatory and immunomodulatory
properties [3].
In experimental allergic encephalomyelitis (EAE), the ani-
mal model of MS, oral statins attenuate the severity of dis-
ease progression by preventing or reversing chronic or
relapsing paralysis. Statin-treated animals show a delayed
onset of first clinical signs and milder clinical signs [4-6].
In an open-label, single-arm study of oral simvastatin (80
mg/d) in patients with RRMS, the mean number and vol-
ume of lesions enhancing with gadolinium (Gd) com-
pared to pre-treatment brain MRI scans declined by 44%
and 41% respectively [7].
In a phase II open-label baseline-to-treatment trial of high
dose atorvastatin monotherapy (80 mg/d) in RRMS there
was a significant decrease in the number and volume of
Gd-enhancing lesions in 24 RRMS patients, and a trend
towards less Gd-enhancing lesions in 12 patients treated
with the combination of atorvastatin (80 mg/d) and IFNB
[8].
An open label study of INFB-1a and atorvastatin in 34
RRMS patients reported good tolerability and no signifi-
cant difference in the clinical outcome measures between
the patients who received IFNB-1a and atorvastatin vs.
patients receiving IFNB-1a alone [9].
An interim analysis of the SIMCOMBIN study with 47
patients randomized to IFNB-1a or the combination of
IFNB-1a and simvastatin 80 mg/d reported a similar
annualized relapse rate [10]. Furthermore, two interim
safety analyses of the current SWABIMS study regarding
the primary endpoint showed no safety concerns.
On the other hand, in a double blind, randomized, pla-
cebo controlled study of twenty-six patients divided in
three groups receiving IFNB-1a (44 ug thrice weekly) and
40 mg atorvastatin per day (7 patients), 80 mg atorvasta-
tin per day (10 patients) or placebo (9 patients) for 6
months, the combination of atorvastatin (40 or 80 mg)
and IFNB-1a resulted in increased MRI and clinical dis-
ease activity [11]. In addition, there are experimental stud-
ies, that suggest a negative impact of statins on
oligodendrocytes and myelin formation with impaired
remyelination [12,13].
Due to the differing results, bigger studies are needed to
provide better evidence on the therapeutic potential of
statins in MS. SWABIMS will give further information of
the efficacy, safety and tolerability of atorvastatin 40 mg
p.o. daily and IFNB-1b e.o.d compared to monotherapy
with IFNB-1b e.o.d. in patients with RRMS.
Methods/Design
SWABIMS is a multi-centre, randomized, parallel-group,
rater-blinded Phase IIb-study conducted in eight hospitals
in Switzerland. Approximately 80 treatment naïve
patients with RRMS (according to McDonald's criteria),
respecting all inclusion and exclusion criteria, will receive
IFNB-1b for 3 months. Afterwards, they will be rand-
omized into two equal-sized parallel arms, receiving ator-
vastatin 40 mg/d or not in addition to IFNB-1b for
another 12 months (Figure 1).
Patients and treating physicians are aware, whether atorv-
astatin is added to IFNB-1b or not. Placebo is not dis-
pensed. Trained and certified examining physicians,
responsible for MRI evaluation and disability scoring
(Expanded Disability Status Scale [EDSS]; Multiple Sclero-
sis Functional Composite [MSFC]) are blinded to the
treatment assignments (= rater-blinded).
The study is conducted in accordance with the ethical
principles of the Declaration of Helsinki, the ICH-GCP
Guidelines of 17 Jan. 1997 (G.U. n 191, 18 Ago 1997) and
with the approval of the local ethics committees and
SWISSmedic, the Swiss authorities for the authorisation
and supervision of therapeutic products (Schweizerisches
Heilmittelinstitut, Hallerstrasse 7, 3000 Bern 9, Switzer-
land; Reference number: 2005DR2119).
Inclusion criteria
Patients with relapsing-remitting forms of MS according
to McDonald's criteria with disease duration > 3 months,
at least 1 relapse in the past two years, ≥ 3 lesions on spi-
nal or brain-MRI or both, baseline-EDSS score from 0 to
3.5 (inclusive), age from 18 to 55 years and normal blood
cell count, renal, and hepatic function values are enrolled.
Women of child-bearing potential have to agree to avoid
pregnancy with appropriate means while on study, and
prior to study entry a negative pregnancy test is manda-
tory.
The main exclusion criteria are primary or secondary pro-
gressive multiple sclerosis (PPMS, SPMS), clinically iso-
lated syndrome (CIS), any disease other than multiplePage 2 of 7
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symptoms, uncontrolled medical or psychiatric condi-
tions, drug abuse, previous therapy at any time with mon-
oclonal antibodies, mitoxantrone, cytotoxic or
immunosuppressive therapy (excluding systemic ster-
oids), total lymphoid irradiation as well as immunomod-
ulatory therapy with IFNB, azathioprine or glatiramer
acetate for 12 months before start of the study, if the pre-
vious treatment has been administrated for ≥12 months.
The primary endpoint is the disease activity measured by
the proportion of patients with new T2 lesions after 15
months of treatment compared to baseline at month 3,
when patients are randomized to receive atorvastatin or
not.
Secondary endpoints are Gd-enhancing lesions on T1-
weighted images, change of total T2 lesion volume (bur-
den of disease, BOD), cortical atrophy (changes in brain
volume, changes in grey matter and white matter), clinical
disease progression (EDSS, MSFC), number of relapse-
free patients, relapse rate, time to first relapse, and serial
levels of neutralizing antibodies (NAbs).
The Multiple Sclerosis Functional Composite (MSFC)
contains the "Timed 25-foot Walk", "9-Hole Peg Test" and
the "Paced Auditory Serial Addition Test" (PASAT) and is,
like the EDSS, performed according to international
standards [14,15].
Treatment
At screening visit, each patient has to provide written
informed consent to the study and an unique patient-
identification number is assigned. Afterwards, inclusion
and exclusion criteria, demographic variables (age [years],
gender, race), medical history (history of MS, general
medical history and physical examinations), physical
examination and vital signs (height [cm], weight [kg],
systolic and diastolic blood pressure [mmHg], body tem-
perature [°C] and pulse rate [bpm]), electrocardiogram
(ECG) and laboratory tests are obtained by a study nurse
and the treating physician. MRI, EDSS and MSFC scoring
are performed by the evaluating physician. Laboratory
tests included haematology values (RBC, WBC, platelets,
differential count, haemoglobin, haematocrit, absolute
lymphocyte count), serum lipids (triglycerides, total cho-
lesterol, free cholesterol, HDL, LDL), serum chemistry
(sodium, potassium, chloride, calcium, urea-N, ALAT,
SWABIMS study designFigure 1
SWABIMS study design. Lab, laboratory tests; INFB-1b, Interferon beta-1b; MRI, magnetic resonance imaging, MSFC, multi-
ple sclerosis functional composite; EDSS, Expanded Disability Status Scale
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bilirubin, creatinine, uric acid, glucose, total protein,
albumin, urinalysis (protein, glucose) and creatine phos-
phokinase (total CPK, isoenzymes).
The randomization of each patient is performed centrally
by the responsible Clinical Research Organisation (CRO)
after the baseline visit. Randomization is conducted in 4-
block size, according to the randomization list (atorvasta-
tin "yes" or "no") generated with "RANCODE Profes-
sional 3.6". This sealed randomization list is stored in the
CRO's archive. At the screening visit, a unique patient-
identification number is assigned to each patient by the
study investigator. A special "subject enrolment form",
including the name of the study site and the unique
patient-identification number is faxed to the CRO by the
investigator of the study site. The CRO performs randomi-
zation according to the randomization list, by using a con-
secutive "randomization form" (atorvastatin "yes" or
"no"), which is faxed back to the study site.
Screening and baseline visit are performed within 30 days.
At baseline visit, inclusion and exclusion criteria are con-
trolled, MSFC scoring is repeated and MRI has to be
accepted centrally by the responsible neuroradiologist.
Afterwards, IFNB-1b is dispensed to all patients. Starting
with 0.0625 mg (2 million units; 0.25 mL) e.o.d., IFNB-
1b is weekly increased by 0.0625 mg to a final dose of
0.25 mg (8 million units; 1 mL).
At month 3, atorvastatin at a daily dose of 40 mg p.o. is
dispensed to patients who were randomized to the atorv-
astatin-group, while IFNB-1b is planned to be on full dos-
age at that time point. The patients who do not receive
atorvastatin continue monotherapy with full-dose IFNB-
1b.
Regular visits at months 1, 3, 4, 6, 9, 12 and 15 are sched-
uled for the assessment and collection of EDSS, MSFC,
MRI, NAbs, laboratory tests as well as other efficacy and
safety data (Figure 1).
Unscheduled visits are performed in case of new, re-
occurring or worsening neurological symptoms suspi-
cious of relapses or medication side effects. Physical
examination with vital signs, EDSS and laboratory tests
are routinely performed.
Relapse definition and treatment
All of the following criteria (1. to 3.) have to be met for a
relapse to be ascertained: 1. neurological abnormality,
either newly appearing or re-appearing, lasting for > 24
hours and being separated by at least 30 days from onset
of a preceding clinical event; 2. Absence of fever or known
infection (fever = > 37.5°C); 3. Objective neurological
impairment, correlating with the patient's reported symp-
toms and increasing the total EDSS score and at least one
of the functional systems of the EDSS score. Fatigue, men-
tal symptoms, and/or vegetative symptoms without any
additional symptoms are not classified as a relapse.
Relapses are recorded and treated with intravenous (iv)
methylprednisolone at a daily dose of 500 mg for five
consecutive days followed by tapering-out with oral pred-
nisolone.
All MRI scans are performed according to a standardized
MRI protocol and will be assessed centrally for number
and volume of lesions and for normalized brain volume
at the Department of Neuroradiology of the University of
Bern [16,17]. Each site has to submit a test scan for
approval of scanning and data transfer prior to study start
and all scanners should have at least 1.5 Tesla magnetic
field strength. MRI scans of the brain will be performed at
screening in order to check MRI inclusion criteria, and this
scan will also serve as the first baseline scan. A second
baseline scan, which will be used for assessment of end-
points, will be acquired 3 months later.
The following order for sequences has to be kept. 1. T1-
weighted axial scout; 2. T1-weighted coronal scout; 3. T1-
weighted sagittal scout; 4. Rapid T1-weighted SE or T2-
weighted FSE/TSE axial (for repositioning check); 5. T2-
weighted FSE/TSE; 6. T1-weighted SE post gadolinium.
T1-weighted sequences of MRI scans are performed with
concentrated (1 mol/L) gadobutrol at a dose of 0.2 mmol
of gadolinium per kilogram of body weight.
Two experienced observers blinded to both clinical events
and treatment are responsible for lesion identification
and counting of all scans. Doubtful cases are assessed by
consensual agreement. The observers are using a semi-
automated program that identifies lesions of T2-weighted
images. All lesions identified by the program have to be
accepted by the investigators as such and investigators can
add lesions not identified by the program. The program is
also able to tell the examiner whether lesions on contigu-
ous slices are part of one or several lesions and how many
lesions have to be counted.
A single T2 lesion is defined as an area of increased signal
on a given 3 mm axial image, which should be seen on
both T2- and proton density-weighted images and which
is not part of normally hyperintense structures. A single
enhancing lesion is defined as an area of enhancement
seen on a 3 mm axial image, which is referable neither to
normally enhanced structures, nor to contrast migration
within vessels. Lesions that change during the study are
categorized as new, enlarging, or recurrent.Page 4 of 7
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The sponsor of this study is the Department of Neurology
of the University Hospital in Bern, Switzerland, repre-
sented by the principal investigator Heinrich Mattle. The
sponsor is responsible for the management of the entire
study including data analysis and interpretation. The
study is conducted independently of the two pharmaceu-
tical companies which provide unrestricted grants for per-
forming the study.
The clinical research organisation (CRO) PharmaPart
GmbH (Bahnhofstrasse 20, Postfach 173, 8800 Thalwil,
Switzerland) is contracted to help for data management,
data analysis, randomization, visit tracking, drug distribu-
tion, case report forms (CRF), adverse and serious adverse
event coding and others. The study statisticians will be
blinded to the treatment-specific data throughout data
collection process and analysis planning.
All laboratory analyses except NAbs are performed cen-
trally by Viollier AG (Spalenring 145, Postfach, 4002
Basel, Switzerland). NAbs are assessed at the Laboratorio
di Neurobiologia Clinica, Ospedale San Luigi Gonzaga
Regione Gonzole, 10, 10043 Orbassano (TO), Italy. The
cytopathic effect (CPE) assay is used to detect NAbs as rec-
ommended by the World Health Organization (WHO)
[18]. Data from the neutralisation assay are reported as
the reciprocal of the highest dilution of serum inducing
50% neutralisation (that is, neutralising 10 U/ml of IFN
activity to an apparent 1 U/ml of activity). The neutralisa-
tion titre of a serum sample is calculated according to
Kawade's formula and expressed in laboratory units (LU).
A concentration of > 20 LU/ml is considered as a positive
result. The IFNB used as reference or calibration standards
in the CPE assay are the commercially available prepara-
tions of Betaferon, Avonex, and Rebif intended for clinical
use [19].
Statistical analysis
Determination of sample size
Data from completed clinical trials suggest that atorvasta-
tin has the potential to increase the proportion of patients
without any new MRI activity by 30% compared to the
IFNB-1b alone. To show such an effect in a trial with 80%
power and a significance level of 5% a sample of 76
patients is required. To allow a withdrawal rate of up to
5% during the trial, it is planned to enter approximately
80 patients.
All statistical analyses will be appropriate to the nature
and distribution of the data collected. Categorical data
will be described by frequency and percentage, continu-
ous data by mean, standard deviation, minimum, 1st quar-
tile, median, 3rd quartile and maximum. Hypothesis tests
will be carried out with an α level of 0.05, two-sided. All
inferential analyses will be presented by p-values, point
estimations and two-sided 95% confidence intervals for
the treatment differences. In case that the assumption of
normality in the linear models is not fulfilled, transforma-
tions of the data or non-parametric approaches like the
Wilcoxon signed rank test will be considered.
Analysis sets are defined as follows
All treated patients population (AT): All enrolled patients
who receive any treatment and who have at least one fol-
low-up efficacy observation independently whether they
are randomized. Intention-to-treat population (ITT): All
randomized patients, who have at least one follow-up
efficacy observation. Per-protocol population (PP): The
per-protocol set includes all patients who essentially com-
plete the randomized part of the study in compliance with
the protocol and who report no major violation.
The primary endpoint is the proportion of patients with
new T2 lesions at month 15 compared to the T2 lesions at
month 3 when patients are randomized to receive atorvas-
tatin or not. Based on a logistic regression model with the
factors treatment and gender and the covariates number
of T2 lesions at baseline, number of Gd-enhancing lesions
at baseline, relapse rate at baseline, baseline EDSS and
time since MS diagnosis the two-sided hypothesis of
equality between the two treatments are tested at an α-
level of 0.05. The results are presented as odds ratios and
the associated two-sided 95% confidence intervals and p-
values. Furthermore, Fisher's exact test for proportions
will be performed to test for the un-adjusted treatment
effect.
Depending on the distribution, secondary efficacy end-
points are analyzed with analysis of covariance or logistic
regression models or exact Fisher's exact tests. Time to
relapse is analyzed with non-parametric methods for fail-
ure time data (Wilcoxon test) and illustrated by a Kaplan-
Meier plot.
Missing data including missing data because of drop-outs
on the primary endpoint (new T2 lesions at month 15)
are replaced with MRI data from month 9. The same
approach is used for the other efficacy endpoints. Missing
values for other parameters will be treated as missing,
except for severity and relationship of adverse events to
study drugs. The number of missing and non-missing val-
ues will be given.
All safety and tolerability assessments are based on the ITT
population and presented by treatment group. Adverse
events are coded using the MedDRA 11.0 dictionary and
concomitant medication using WHO-Drug 2007.1. Treat-Page 5 of 7
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study) are summarized by presenting the number and per-
centage of subjects having an event and the number and
percentage of events in each system organ class and pre-
ferred term for each treatment group. Subjects who have
multiple events in the same system organ class and pre-
ferred term are counted only once at each level of summa-
tion (overall, by system organ class, and by preferred
term).
Discussion
Statins have anti-inflammatory and immunomodulatory
properties in addition to their lipid-lowering effects. The
effects of statins on the course multiple sclerosis are still
unknown. Experimental and clinical studies have given
differing results and results from randomized trials are
missing.
The Swiss Atorvastatin and Interferon Beta-1b Trial In
Multiple Sclerosis (SWABIMS) is a multi-centre, rand-
omized, parallel-group, rater-blinded Phase IIb-study
conducted to assess the efficacy, safety and tolerability of
atorvastatin 40 mg (p.o.) daily and IFNB-1b e.o.d com-
pared to monotherapy with IFN-1b e.o.d. in patients with
RRMS.
SWABIMS will likely give further information about the
therapeutic potential of atorvastatin 40 mg p.o. daily as
add-on therapy to IFNB-1b e.o.d in patients suffering
from RRMS. In addition, SWABIMS will provide impor-
tant safety and tolerability data of atorvastatin in patients
with RRMS.
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